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Abstract
Background: Medulloblastoma is the most common malignant brain tumour of childhood. The identification of critical
genes involved in its pathogenesis will be central to advances in our understanding of its molecular basis, and the
development of improved therapeutic approaches.
Methodology/Principal Findings: We performed a SNP-array based genome-wide copy number analysis in medulloblas-
toma cell lines, to identify regions of genomic amplification and homozygous deletion, which may harbour critical disease
genes. A series of novel and established medulloblastoma defects were detected (MYC amplification (n= 4), 17q21.31 high-
level gain (n= 1); 9p21.1–p21.3 (n= 1) and 6q23.1 (n= 1) homozygous deletion). Most notably, a novel recurrent region of
genomic amplification at 8q24.22–q24.23 was identified (n= 2), and selected for further investigation. Additional analysis by
interphase fluorescence in situ hybridisation (iFISH), PCR-based mapping and SNP-array revealed this novel amplification at
8q24.22–q24.23 is independent of MYC amplification at 8q24.21, and is unique to medulloblastoma in over 800 cancer cell
lines assessed from different tumour types, suggesting it contains key genes specifically involved in medulloblastoma
development. Detailed mapping identified a 3Mb common minimal region of amplification harbouring 3 coding genes
(ZFAT1, LOC286094, KHDRBS3) and two genes encoding micro-RNAs (hsa-miR-30b, hsa-miR-30d). Of these, only expression of
hsa-miR-30b, hsa-miR-30d and KHDRBS3 correlated with copy number status, and all three of these transcripts also
displayed evidence of elevated expression in sub-sets of primary medulloblastomas, measured relative to the normal
cerebellum.
Conclusions/Significance: These data implicate hsa-miR-30b, hsa-miR-30d and KHDRBS3 as putative oncogenic target(s) of
a novel recurrent medulloblastoma amplicon at 8q24.22–q24.23. Our findings suggest critical roles for these genes in
medulloblastoma development, and further support the contribution of micro-RNA species to medulloblastoma
pathogenesis.
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Introduction
Medulloblastoma is an invasive embryonal tumour of the
cerebellum, and the most common malignant brain tumour in
children. Although overall five-year survival rates of 60–70% are
now achieved, a significant proportion of cases will die from their
disease, and the intensive chemotherapeutic and radiotherapy
regimes employed in treatment are associated with long-term
neuroendocrine and cognitive dysfunction in surviving patients.
Advances in our understanding of the biology of medulloblastoma
will be essential to future improvements in therapeutic outcome,
through strategies including the identification of specific targets for
the development of novel therapies, and biomarkers for improved
treatment stratification [1,2].
The identification of specific genetic defects has been central to
advances in our understanding of the molecular basis of
medulloblastoma. A series of non-randomly mutated genes have
been identified, which have, in turn, led to the characterisation of
critical roles for their associated biological pathways in sub-sets of
cases; the Wnt/Wingless (WNT) signalling pathway is activated by
mechanisms including CTNNB1 mutation in 10–15% cases, and
the Sonic hedgehog (SHH) pathway in activated in a further 20–
25%, predominantly by mutations in PTCH1 [1–5]. The most
prevalent genomic amplifications reported to date affect the MYC
and MYCN oncogenes (each in 5–15% of cases), and homozygous
deletions of established tumour suppressor genes, including
CDKN2A and P14ARF, have been described [6–8]. Importantly,
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genetic defects have therapeutic relevance; markers of favourable
(WNT activation) and poor (MYC/MYCN amplification) prognosis
have been identified and validated in clinical trials cohorts
[6,9,10], and small molecule inhibitors of the SHH pathway are
under pre-clinical development [11].
Despite these advances, the critical genes involved in medullo-
blastoma development are otherwise poorly understood, and
specific genetic defects remain to be identified in the majority of
cases. We therefore undertook a comprehensive SNP-array based
analysis of copy number defects in medulloblastoma cell lines, to
identify regions of genomic amplification and homozygous
deletion, which may harbour critical medulloblastoma genes. We
report the validation, mapping and further characterisation of
recurrent novel genetic regions identified, in medulloblastoma cell
lines and primary tumours, and use these data to identify putative
target gene(s) which may contribute to medulloblastoma develop-
ment.
Methods
Primary tumours, tissues and cell lines
37 primary medulloblastoma samples were analysed in this
study. The cohort included 22 male and 14 female patients (1
unknown), aged 1.3 to 40 years at diagnosis (1 infant (,3 years), 31
children ($3 to 15 years) and 4 adults ($16 years)). Histopath-
ological review identified 27 cases of classic medulloblastoma, 4
cases of nodular/desmoplastic medulloblastoma, 5 cases of large-
cell/anaplastic medulloblastoma and one case of undefined
histological variant [12]. Four non-neoplastic cerebellar samples
(aged 10 months to 67 years) were also investigated. All aspects of
this study have been approved by the Newcastle & North Tyneside
NHS Trust research ethics committee (approval 07/Q0905/71).
Written Informed consent for tumour collection, storage and
research was obtained for all primary medulloblastomas, from
participants or their parents/legal guardians. Under the terms of
the research ethics committee approval for this study, and the UK
Human Tissue Act (2006), consent was not required for the
normal cerebellar material, as it was collected prior to 2006. Eight
medulloblastoma cell lines were investigated (DAOY, D384MED,
D425MED, D458MED, D341MED, D283MED, MHH-MED-1,
MHH-MED-8A), cultured and maintained as previously described
(Langdon et al. 2006). Genomic DNA from samples was extracted
using the Nucleon hard tissue kit (Nucleon Biosciences) or by the
TRIzol method (Invitrogen), according to the manufacturer’s
instructions. RNA was extracted from samples using the TRIzol
method (Invitrogen), and treated with DNAse I (Ambion) to
eliminate contaminating DNA.
SNP-array analysis
Genomic DNA samples from the eight medulloblastoma cell
lines were analysed using the GeneChipHMapping 10K 2.0 Array
(Affymetrix), and raw data processed using Microsoft Excel
spreadsheets, as previously described [13]. The raw SNP array
data is available freely from the Cancer Genome Project, subject
to completion of a data access agreement (http://www.sanger.ac.
uk/genetics/CGP/Archive/). Data were used to identify markers
displaying evidence of genomic amplification or homozygous
deletion, which were defined as follows: intensity ratio (or haploid
copy number (HCN)).2.5, amplification or high-level gain;
HCN,0.1, homozygous deletion. Physical positions of probes
and genes were identified according to the SNP consortium (TSC)
database (http://www.hapmap.org/) and the NCBI database
build 36.2 (http://www.ncbi.nih.nlm.gov). The estimated maxi-
mal regions of continuous defects affecting multiple probes were
identified by the physical positions of the nearest flanking
unaffected probe at each end.
Quantitative real-time PCR
Analysis of hsa-miR-30b and hsa-miR-30d expression, mea-
sured relative to a U6 non-coding RNA control, was performed
using proprietary TaqManH MicroRNA real-time PCR Assay
primer sets and reagents (Applied Biosystems), based on absolute
quantification, following the manufacturer’s instructions. All other
analyses were performed using real-time PCR, based on the SYBR
Green JumpStart Taq ReadyMix system (Sigma). Absolute
quantification was applied to copy number analysis, whereas
relative quantification was applied to expression analysis. B2M,
RPLP0 and TBP were used as reference genes for copy number
analysis, and 28s rRNA was used as the reference gene for
expression analysis. Details of primers used for these PCRs are
shown in Supplementary Tables S1, S2 & S3. All real-time PCR
assays were undertaken on an ABI PRISM 9700HT (Applied
Biosystems) real-time PCR system.
Fluorescence in situ hybridisation
Interphase fluorescence in situ hybridization (iFISH) was
performed in medulloblastoma cell lines using BAC clones
RP11-383N10 (representing sequences at 8q24.23; obtained from
The Wellcome Trust Sanger Institute, Cambridge), dJ968N11
(representing MYC [6]) and pZ8.4 (representing the centromere of
chromosome 8 [6]), as previously described [6,14].
Results
SNP-array based copy number analysis of
medulloblastoma cell lines: Identification of a novel
region of recurrent genomic amplification at 8q23.22–
q23.24 specific to medulloblastoma
Raw 10K SNP-array data generated from 8 medulloblastoma
cell lines were analysed and converted to graphical plots, as
previously described [13]. Wider chromosomal defects identified
were consistent with our previous genome-wide studies of these
cell lines using loss of heterozygosity and conventional compar-
ative genomic hybridisation methods (data not shown [14]).
However, high-resolution SNP array identified a number of focal
defects for further investigation, and we elected to focus our
analysis on these regions of putative genomic amplification or
homozygous deletion, which may contain critical oncogenes or
tumour suppressor genes in medulloblastoma development.
Defects affecting at least three consecutive markers were classified
as significant and, using these criteria, evidence of both genomic
amplifications and homozygous deletions were observed
(Figure 1A), which are summarised in Figure 1B. The majority
of these regions either harboured known critical cancer-related
genes or affected previously described features of medulloblasto-
ma; amplification of MYC at 8q24.21, a well established feature of
medulloblastoma [1,2,6], was the only recurrent event detected
which affected an established cancer-related gene, seen in 4/8 cell
lines analysed. Homozygous deletions of (i) the 9p21.1–p21.3
region encompassing CDKN2A, CDKN2B and ARF and (ii) the
6q23.1 region, each observed in a single cell line, have previously
been reported in medulloblastoma and other cancer types
[7,8,15,16]. A novel high level gain/amplification at 17q21.31,
in conjunction with evidence of isochromosome (17q) (i(17q)) (i.e.
gain of the q-arm and loss of the p-arm of chromosome 17), the
most common cytogenetic feature of medulloblastoma [1,2], was
found in the D425MED line.
8q24 Genes in Medulloblastoma
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Figure 1. Homozygous deletions and genomic amplifications/high level gains identified in medulloblastoma cell lines. [A] Illustrative
copy number studies for medulloblastoma cell lines showing defects detected by the SNP-array analysis. Data were analysed and displayed as
previously described (Bignell, Huang et al. 2004). Probes are displayed by their physical position on the chromosome (X-axis), from p-ter to q-ter (left
to right). The smoothed intensity ratio, based on a ‘moving window’ average of five adjacent probes is indicated by the Y-value. Mean values for a
panel of 29 normal samples are represented by the grey dots, while the values of the medulloblastoma cell line are shown in black. In this figure, two
independent amplifications/high level gains at 8q24 are shown in D341MED and D384MED, as well as an amplification/high level gain at 17q21 in
D425MED and a homozygous deletion at 9p21 in DAOY. [B] Detailed information for defects identified affecting more than two adjacent markers.
Estimated maximal cytogenetic and physical positions of each defect are shown, as well as any known key cancer-related gene contained within the
region. HCN, estimated haploid copy number; HLG/AMP, high level gain or genomic amplification; HD, homozygous deletion.
doi:10.1371/journal.pone.0006159.g001
8q24 Genes in Medulloblastoma
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Notably, a single novel region of recurrent genomic high level
gain/amplification was observed, at 8q23.22–q23.24, in two
independent medulloblastoma cell lines (D341MED and
D384MED). This novel feature at 8q24.22–q24.23 is of particular
interest since (i) it was observed in multiple cell lines, and (ii) no
evidence of amplification at this region was found in the analysis of
over 800 other cancer cell lines derived from a wide range of
different paediatric and adult cancer types using the GeneChipH
Mapping 10K 2.0 Array (http://www.sanger.ac.uk/cgi-bin/
genetics/CGP/cghviewer/CghHome.cgi), suggesting this putative
amplicon may contain gene(s) specifically related to medulloblas-
toma development. Additionally, we confirmed the independence
of the D341MED and D384MED cell lines; each displayed a
unique allelotype and harboured distinct genomic defects [14].
Therefore, we elected to further characterise this novel region in
detail, and its role in medulloblastoma.
Verification, characterisation and physical mapping of
the novel amplification at 8q24.22–q24.23 in
medulloblastoma cell lines
The novel high-level gain/amplification observed at 8q24.22–
q24.23 in D341MED and D384MED cell lines by SNP array was
next investigated independently by iFISH. The BAC-clone RP11-
383N10, which represents DNA sequences within this amplicon
(Figure 2E), was used as a probe, and confirmed the presence of
DNA amplification (.10 copies per control centromeric signal) in
both cell lines (Figures 2A & B), but not in the other cell lines
examined (data not shown).
We noted that amplification of MYC at 8q24.21 and the novel
region at 8q24.22–q24.23 was co-incident in both D341MED and
D384MED. Although SNP-array data indicate that the regions of
amplification are discrete (Figure 1A), the relationship between
this novel amplification and MYC amplification at 8q24.21, was
assessed by co-hybridization of RP11-383N10 and BAC probe
dJ968N11, recognising MYC, in D384MED cells, to investigate
whether their amplification was co-localised on a single amplicon.
The combined result from over 100 cells indicated a mixed pattern
of amplification in the cell population; MYC amplification alone
was observed in 32% of cells, while the novel amplification alone
was observed in 28% of the cell population. 22% of the cells
showed amplification of both regions, but in two thirds of these
cells, signals generated by the two BAC probes were not co-
localised (Figure 2C).
The amplification status and physical gene content of the novel
amplicon was additionally investigated using real-time PCR-based
mapping. Analysis of the status of the coding genes within and
surrounding the putative amplicon (Figure 2E) showed that
ZFAT1, LOC286094 and KHDRBS3 were amplified in both cell
lines D341MED and D384MED, but not in the non-amplified
MHH-MED-8A line. The flanking genes, ST3GAL1 and
FLJ45872, at the proximal and distal ends respectively of the
amplified region, did not shown any evidence of amplification in
any cell line (Figure 2F). LOC100130092, which encodes a
predicted psudogene within the amplified region on the NCBI
database (http://www.ncbi.nlm.nih.gov/), was not investigated.
By SNP-array, physical mapping identified the amplicon extend-
ing from 134,810,164 bp (tsc0062042) to 137,820,222 bp
(tsc0696464) in D341MED, and from 134,810,164 bp
(tsc0062042) to 137,858,383 bp (tsc1392944) in D384MED,
indicating a maximal common region of 3 Mb, extending from
134,810,164 bp to 137,820,222 bp.
Together, these data indicate that the novel amplification at
8q24.22–q24.23 is independent of MYC amplification and has
consecutive gene content in both D341MED and D384MED, with
the involved regions extending from ZFAT1 at its proximal end to
KHDRBS3 at its distal end, and also encompasses LOC286094 and
two genes encoding micro-RNAs (mi-RNAs), hsa-miR-30b and
hsa-miR-30d.
Identification of putative target gene(s) of the novel
amplification at 8q24.22–q24.23: investigation of
relationships between gene amplification and transcript
levels
To identify potential target genes of the novel amplification
which may contribute to tumourigenesis, relationships between the
transcript levels and copy numbers of genes contained in the novel
amplicon were assessed in medulloblastoma cell lines using real-
time PCR methods. High-level expression of hsa-miR-30b and
hsa-miR-30d was closely correlated with their copy number status
(Figures 3A & B), suggesting these may represent targets. No
evidence of high-level expression of ZFAT1 or LOC286094, or
correlation with gene copy number, was found in any cell line
(data not shown), suggesting these do not represent candidate
target genes. Data obtained for KHDRBS3 were less clear; high-
level expression was seen in three cell lines, however only one cell
line of the three harboured the amplification, while no evidence of
high-level expression was observed in the other amplified cell line
(Figure 3C). Based on these findings, we next investigated the
expression of the two mi-RNAs and KHDRBS3 in primary
medulloblastomas and normal cerebellum, to further explore any
roles in medulloblastoma development.
Transcript levels of candidate amplicon target genes and
miRNAs in primary medulloblastomas and the normal
cerebellum
Expression of mature hsa-miR-30b and hsa-miR-30d, as well as
KHDRBS3, was analysed in cohorts of primary medulloblastoma
samples, alongside four normal cerebellar samples, and data for
medulloblastoma cell lines (n = 8) (Figure 4). The highest mean
level of expression observed in a normal cerebellar tissue sample
was used as a threshold for the determination of overexpression in
primary tumours and cell lines. Using these criteria, 54% (14/26),
12% (3/26) and 15% (3/20) of primary medulloblastomas showed
evidence of overexpression of hsa-miR-30b, hsa-miR-30d, and
KHDRBS3, respectively (Figure 4). High-level expression of hsa-
miR-30b, comparable to levels observed in 8q24.22–q24.23
amplified cell lines, was observed in a sub-set of primary tumours.
High-level expression of KHDRBS3, equivalent to levels observed
in an 8q24.22–q24.23 amplified cell line, was also observed in a
sub-set of primary tumours and other cell lines, but was not
restricted to the 8q24.22–q24.23 amplified cell lines. Although
expression levels of hsa-miR-30d in primary tumours were
elevated relative to the normal cerebellum, they did not approach
levels observed in 8q24.22–q24.23 amplified cell lines.
Analysis of genetic amplification at 8q24.22–q24.23 in
primary medulloblastomas
The relative copy number of KHDRBS3, as a marker of the
novel amplicon at 8q24.22–q24.23, was determined in all primary
medulloblastoma samples in which the expression level was
assessed (n = 37) by qPCR; no evidence of genomic amplification
was observed (data not shown).
Discussion
This genome-wide SNP-array based screen has facilitated the
characterisation of a series of focal regions of gene amplification
8q24 Genes in Medulloblastoma
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Figure 2. Verification and physical mapping of the novel amplification at 8q24.22–q24.23 in medulloblastoma cell lines. iFISH
analysis using the RP11-383N10 and chromosome 8 centromeric probes in [A] D341MED and [B] D384MED. Red signals represent the chromosome 8
centromeric probes, and the green signals represent the RP11-383N10 probes. iFISH analyses using the RP11-383N10 and MYC probes are shown in
[C] D384MED and [D] D458MED. Red signals represent the MYC probes, and the green signals represent the RP11-383N10 probes. Nuclei were
counter-stained using DAPI (blue) in all experiments. Magnifications are indicated. [E] A physical map of the novel amplicon at 8q24.22–q24.23
identified in medulloblastoma cell lines. The putative minimal common region of amplification identified by SNP array analysis is indicated by the two
vertical dotted lines with solid ends. The position of the BAC-clone used for FISH analysis is indicated by the grey bar. [F] Real-time PCR analysis of the
relative copy number status of genes located within and around the novel amplicon at 8q24.22–q24.23 in the medulloblastoma cell lines D341MED,
D384MED and MHH-MED8A. The relative copy number of each candidate gene is shown relative to the reference gene, B2M, and is shown as a log10
scale. Two replicate analyses of each sample were performed and the mean value is shown.
doi:10.1371/journal.pone.0006159.g002
8q24 Genes in Medulloblastoma
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and homozygous deletion in medulloblastoma, and the identifica-
tion of putative target genes which may play critical roles in its
development, and have therapeutic significance. In addition to the
identification and further validation of established genomic events
in medulloblastoma (e.g. MYC amplification, CDKN2A/B homo-
zygous deletion [1,2,6–8]), defects have been identified which will,
following further validation, aid investigations of the critical
genetic targets of common medulloblastoma chromosomal
aberrations. i(17q) is the most common chromosomal defect in
medulloblastoma, affecting 30–40% of cases, and chromosome 6
loss is characteristic of the molecular disease sub-group defined by
activation of the Wnt/Wingless cell signalling pathway [1–5]. The
respective high level gain/amplification identified at 17q21.31,
and the homozygous deletion at 6q23.1, will yield candidate target
genes and facilitate the further mapping and investigation of these
chromosomal aberrations.
The novel region of recurrent amplification identified at
8q24.33–q24.23 formed the focus of our further investigations.
In addition to its recurrent nature, we have demonstrated its high-
copy number amplification, independence of MYC amplification,
and uniqueness to medulloblastoma amongst a panel of .800 cell
lines derived from different tumour types, indicating this novel
amplicon contains key gene(s) in medulloblastoma development,
with the potential to inform critical insights to disease pathogen-
esis. The identification of the genetic target(s) of this novel
amplicon, and their validation in studies of primary tumours, and
in functional models, is therefore now paramount. Our detailed
genetic mapping of its physical location and gene content, and
investigation of their relationship to gene expression in medullo-
blastoma cell lines, identified KHSRBS3 and the genes encoding
mi-RNA species, hsa-miR-30b and hsa-miR-30d, as putative
oncogenic targets whose expression is closely correlated with
amplification status.
In primary tumours, although we did not detect evidence of
amplification of this target region in our cohort of primary
medulloblastomas, consistent with data from a recent SNP-array
screen of 212 primary medulloblastomas [8], our investigations of
the transcript levels of these target species further support roles in
medulloblastoma. Based on these data, all three candidates,
KHSRBS3, hsa-miR-30b and hsa-miR-30d, could be considered as
potential targets of this novel amplification, as all showed elevated
expression in a sub-set of primary medulloblastomas, measured
Figure 3. Association between transcript level and copy number of genes located in the novel amplicon at 8q24.22–q24.23 in
medulloblastoma cell lines. [A] hsa-miR-30b [B] hsa-miR-30d [C] KHDRBS3. Linear regression analyses were performed and the r2 values are
indicated.
doi:10.1371/journal.pone.0006159.g003
8q24 Genes in Medulloblastoma
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Figure 4. Transcript levels of hsa-miR-30b, hsa-miR-30d and KHDRBS3 in primary medulloblastoma tumours and the normal
cerebellum. Expression of each candidate relative to its reference gene is indicated in the Y-axis. The samples were grouped into three categories
(X-axis): medulloblastoma cell lines, primary medulloblastoma tumours and normal non-neoplastic cerebellum, and are shown from left to right in
order from the highest expression level to the lowest in each group. Three replicate analyses were performed for each sample. Mean results and
standard errors (represented by the error bars) are shown. The threshold for overexpression detection is indicated by the dotted line. * indicates the
two cell lines harbouring the novel amplification at 8q24.22–q24.23.
doi:10.1371/journal.pone.0006159.g004
8q24 Genes in Medulloblastoma
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relative to the normal cerebellum. hsa-miR-30b is arguably of
most interest because, in addition to its high-level expression in cell
lines which is closely correlated with amplification, it showed the
greatest frequency of elevated expression in primary tumours (over
50% of cases), with expression levels detected in certain cases
equivalent to those observed in amplified cell lines. Although such
investigations were beyond the scope of the limited initial primary
tumour cohort employed in the current study, the clinico-
pathological correlates of expression of all candidates in extensive,
well characterised, and statistically powered clinical cohorts, is
additionally likely to inform any potential roles in medulloblasto-
ma.
Importantly, none of the three candidates can be fully excluded
at this stage, and further investigations of their functional roles in
medulloblastoma are required. The function(s) of KHDRBS3, hsa-
miR-30b and hsa-miR-30d, and in particular any roles they may
play in tumourigenesis, have not been widely investigated, and this
is the first study, to our knowledge, to investigate their status in
medulloblastoma. KHDRBS3 (KH domain containing, RNA
binding, signal transduction associated 3) belongs to a RNA
binding protein family, and regulates the variant splicing of certain
target genes [17]. Although one published study has demonstrated
that expression of KHDRBS3 positively regulates telomerase
activity in human colon cancer HCT-116 cells [18], further details
of KHDRBS3 function and association with cancers are not clear.
Similarly, hsa-miR-30b and hsa-miR-30d have not been well
characterised. Array-based studies have confirmed their expression
in human tissues [19–21], however on-line databases (e.g.
miRBase; http://microrna.sanger.ac.uk/) predict .800 mRNA
targets for each species, and their specific functions remain
unclear. Nonetheless, the amplification and overexpression of hsa-
miR-30b and hsa-miR-30d in medulloblastoma further supports
an emerging role for the dysregulation of mi-RNA species in
medulloblastoma development [22–26].
In summary, we have described a genome-wide screen of
medulloblastoma cell lines to identify and characterise regions of
gene amplification and homozygous deletion which may harbour
critical genes in its development. Our findings implicate hsa-miR-
30b, hsa-miR-30d and KHDRBS3 as putative oncogenic target(s) of
a novel recurrent medulloblastoma amplicon at 8q24.22–q24.23,
which is independent of MYC amplification and unique to this
disease. These data suggest specific and critical roles for these
genes in medulloblastoma development for wider investigation,
and further support the contribution of mi-RNA species to
medulloblastoma pathogenesis.
Supporting Information
Table S1 Primers for real-time PCR analysis of the genomic
copy number status of genes contained within the novel amplicon
at 8q24.22–q24.23. All sequences are shown in the 59 to 39
direction. F-forward, R-reverse. The predicted length of each
PCR product is shown in base pairs (bp). The annealing
temperature for all PCRs shown was 60uC.
Found at: doi:10.1371/journal.pone.0006159.s001 (0.04 MB
DOC)
Table S2 Primers for real-time PCR analysis of transcript
expression of genes contained within the novel amplicon at
8q24.22–q24.23. All sequences are shown in the 59 to 39 direction.
F-forward, R-reverse. The predicted length of each PCR product
is shown in base pairs (bp). The annealing temperature for all
PCRs shown was 60uC. Primers recognising ZFAT1 and
KHDRBS3 genes were designed to span two or more exons, to
control against contamination by genomic DNA sequences.
Found at: doi:10.1371/journal.pone.0006159.s002 (0.03 MB
DOC)
Table S3 Primers for real-time PCR analysis of copy number
status of KHDRBS3 in primary medulloblastoma samples. All
sequences are shown in the 59 to 39 direction. F-forward, R-
reverse. The putative length of each PCR product is shown in base
pairs (bp). The annealing temperature for all PCRs shown was
60uC.
Found at: doi:10.1371/journal.pone.0006159.s003 (0.03 MB
DOC)
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